clofop (BioDeep_00000012592)
Secondary id: BioDeep_00001871273
代谢物信息卡片
2-[3-(4-Chlorophenoxy)phenoxy]propanoic acid
化学式: C15H13ClO4 (292.0502)
中文名称: 2-(4-(4-氯苯氧基)苯氧基)丙酸
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C(=O)O)OC1=CC=C(C=C1)OC2=CC=C(C=C2)Cl
InChI: InChI=1S/C15H13ClO4/c1-10(15(17)18)19-12-6-8-14(9-7-12)20-13-4-2-11(16)3-5-13/h2-10H,1H3,(H,17,18)
描述信息
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
D009676 - Noxae > D000963 - Antimetabolites
同义名列表
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:82195
- KEGG: C19070
- PubChem: 64928
- PubChem: 53297419
- Metlin: METLIN72818
- CAS: 26129-32-8
- PMhub: MS000026913
- PubChem: 124489742
- KNApSAcK: 82195
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Manuel E Machado-Duque, Andrés Gaviria-Mendoza, Jorge E Machado-Alba. Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia.
Journal of primary care & community health.
2020 Jan; 11(?):2150132720977733. doi:
10.1177/2150132720977733. [PMID: 33251941] - Ji Soo Han, Kyu Kim, Youngae Jung, Jae-Hwan Lee, June Namgung, Hae-Young Lee, Jon Suh, Geum-Sook Hwang, Sang-Hak Lee. Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin.
Scientific reports.
2018 10; 8(1):14642. doi:
10.1038/s41598-018-33058-x. [PMID: 30279504] - Anja Coors, Pia Vollmar, Frank Sacher, Christian Polleichtner, Enken Hassold, Daniela Gildemeister, Ute Kühnen. Prospective environmental risk assessment of mixtures in wastewater treatment plant effluents - Theoretical considerations and experimental verification.
Water research.
2018 09; 140(?):56-66. doi:
10.1016/j.watres.2018.04.031. [PMID: 29684702] - Chaorui Guo, Siqi Xue, Xiufen Zheng, Yang Lu, Di Zhao, Xijing Chen, Ning Li. The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Apr; 48(4):400-406. doi:
10.1080/00498254.2017.1306760. [PMID: 28287050] - Tae Kon Kim. Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate.
Drug research.
2017 Sep; 67(9):534-538. doi:
10.1055/s-0043-109243. [PMID: 28561239] - Xudan Wei, Ping Li, Meina Liu, Yuqian Du, Menglin Wang, Jinling Zhang, Jing Wang, Hongzhuo Liu, Xiaohong Liu. Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry.
Biomedical chromatography : BMC.
2017 Apr; 31(4):. doi:
10.1002/bmc.3832. [PMID: 27594083] - Katarina Bukara, Laurent Schueller, Jan Rosier, Mark A Martens, Tinne Daems, Loes Verheyden, Siemon Eelen, Michiel Van Speybroeck, Cristian Libanati, Johan A Martens, Guy Van Den Mooter, Françoise Frérart, Koen Jolling, Marjan De Gieter, Branko Bugarski, Filip Kiekens. Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2016 Nov; 108(?):220-225. doi:
10.1016/j.ejpb.2016.08.020. [PMID: 27648957] - Kyeong Soo Kim, Jeong Hyun Kim, Sung Giu Jin, Dong Wuk Kim, Dong Shik Kim, Jong Oh Kim, Chul Soon Yong, Kwan Hyung Cho, Dong Xun Li, Jong Soo Woo, Han-Gon Choi. Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.
Archives of pharmacal research.
2016 Apr; 39(4):531-538. doi:
10.1007/s12272-015-0701-9. [PMID: 26992922] - Ignacio Vayá, Inmaculada Andreu, Vicente T Monje, M Consuelo Jiménez, Miguel A Miranda. Mechanistic Studies on the Photoallergy Mediated by Fenofibric Acid: Photoreactivity with Serum Albumins.
Chemical research in toxicology.
2016 Jan; 29(1):40-6. doi:
10.1021/acs.chemrestox.5b00357. [PMID: 26633742] - Lori A Gordon, Christine Y Malati, Colleen Hadigan, Mary McLaughlin, Raul M Alfaro, Mónica M Calderón, Joseph A Kovacs, Scott R Penzak. Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
Pharmacotherapy.
2016 Jan; 36(1):49-56. doi:
10.1002/phar.1682. [PMID: 26799348] - Liang Yang, Yating Shao, Hyo-Kyung Han. Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.
International journal of nanomedicine.
2016; 11(?):1067-76. doi:
10.2147/ijn.s101116. [PMID: 27042061] - Bobeck S Modjtahedi, Namrata Bose, Thanos D Papakostas, Lawrence Morse, Demetrios G Vavvas, Amar U Kishan. Lipids and Diabetic Retinopathy.
Seminars in ophthalmology.
2016; 31(1-2):10-8. doi:
10.3109/08820538.2015.1114869. [PMID: 26959124] - Loreto Quesada, Isabel Gomila, Antonia Fe, Miguel A Servera, Christopher Yates, Daniel Morell-Garcia, Bartomeu Castanyer, Bernardino Barceló. Fenofibric Acid Can Cause False-Positive Urine Methylenedioxymethamphetamine Immunoassay Results.
Journal of analytical toxicology.
2015 Nov; 39(9):734-40. doi:
10.1093/jat/bkv074. [PMID: 26203185] - Sumon Roy, Dongjoon Kim, Cristina Hernández, Rafael Simó, Sayon Roy. Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.
Experimental eye research.
2015 Nov; 140(?):124-129. doi:
10.1016/j.exer.2015.08.010. [PMID: 26297615] - Sana Raza-Iqbal, Toshiya Tanaka, Motonobu Anai, Takeshi Inagaki, Yoshihiro Matsumura, Kaori Ikeda, Akashi Taguchi, Frank J Gonzalez, Juro Sakai, Tatsuhiko Kodama. Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.
Journal of atherosclerosis and thrombosis.
2015 Aug; 22(8):754-72. doi:
10.5551/jat.28720. [PMID: 26040752] - Kyung Soo Kim, Sung Giu Jin, Omer Mustapha, Abid Mehmood Yousaf, Dong Wuk Kim, Young Hun Kim, Jong Oh Kim, Chul Soon Yong, Jong Soo Woo, Han-Gon Choi. Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.
International journal of pharmaceutics.
2015 Jul; 490(1-2):273-80. doi:
10.1016/j.ijpharm.2015.05.059. [PMID: 26024820] - Erik Sjögren, David Dahlgren, Carl Roos, Hans Lennernäs. Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data.
Molecular pharmaceutics.
2015 Jun; 12(6):2026-39. doi:
10.1021/mp500834v. [PMID: 25919764] - M Grabacka, P Waligorski, A Zapata, D A Blake, D Wyczechowska, A Wilk, M Rutkowska, H Vashistha, R Ayyala, T Ponnusamy, V T John, F Culicchia, A Wisniewska-Becker, K Reiss. Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
2015 Apr; 66(2):233-47. doi:
NULL. [PMID: 25903954] - Yunxia Lu, Jingjing Cheng, Li Chen, Chaofei Li, Guanjun Chen, Li Gui, Bing Shen, Qiu Zhang. Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention.
Biochemical and biophysical research communications.
2015 Feb; 458(1):1-7. doi:
10.1016/j.bbrc.2014.12.123. [PMID: 25592967] - Roger K Verbeeck, Sophie De Niet, Sonia Lebrun, Mickael Tremege, Tim W Rennie, Monte Coffiner, Bruno Streel, Bernard Cahay. The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2015; 18(1):61-7. doi:
10.18433/j3fg7g. [PMID: 25877442] - Siddharth S Chachad, Milind Gole, Geena Malhotra, Raghu Naidu. Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects.
Clinical therapeutics.
2014 Jun; 36(6):967-73. doi:
10.1016/j.clinthera.2014.04.017. [PMID: 24844853] - Michael H Davidson, Robert S Rosenson, Kevin C Maki, Stephen J Nicholls, Christie M Ballantyne, Theodore Mazzone, Dawn M Carlson, Laura A Williams, Maureen T Kelly, Heidi S Camp, Aditya Lele, James C Stolzenbach. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Arteriosclerosis, thrombosis, and vascular biology.
2014 Jun; 34(6):1298-306. doi:
10.1161/atvbaha.113.302926. [PMID: 24743431] - Zhongxiao Wang, Elizabeth Moran, Lexi Ding, Rui Cheng, Xun Xu, Jian-xing Ma. PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway.
Investigative ophthalmology & visual science.
2014 May; 55(6):3820-32. doi:
10.1167/iovs.13-13396. [PMID: 24845641] - Nrupa Borkar, Dengning Xia, René Holm, Yong Gan, Anette Müllertz, Mingshi Yang, Huiling Mu. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2014 Jan; 51(?):204-10. doi:
10.1016/j.ejps.2013.09.022. [PMID: 24134899] - Minako Karahashi, Hiroto Fukuhara, Miki Hoshina, Takeshi Sakamoto, Tohru Yamazaki, Atsushi Mitsumoto, Yoichi Kawashima, Naomi Kudo. A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography.
Biological & pharmaceutical bulletin.
2014; 37(1):105-12. doi:
10.1248/bpb.b13-00631. [PMID: 24389487] - Ngoc-Anh Le, Monica Farkas-Epperson, Mary Ellen Sweeney, Peter W F Wilson, W Virgil Brown. Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome.
Atherosclerosis.
2013 Dec; 231(2):268-73. doi:
10.1016/j.atherosclerosis.2013.09.022. [PMID: 24267238] - Debra L Weinstein, Laura A Williams, Dawn M Carlson, Maureen T Kelly, Kim M Burns, Carolyn M Setze, Aditya Lele, James C Stolzenbach. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Clinical therapeutics.
2013 Aug; 35(8):1186-98. doi:
10.1016/j.clinthera.2013.06.013. [PMID: 23891363] - Licht Miyamoto, Masashi Watanabe, Chiaki Taoka, Mai Kono, Yosuke Tomida, Tsuyoshi Matsushita, Masaki Kamiya, Hatsuhiko Hattori, Keisuke Ishizawa, Shinji Abe, Hisao Nemoto, Koichiro Tsuchiya. A novel prodrug strategy for extremely hydrophobic agents: conjugation to symmetrically branched glycerol trimer improves pharmacological and pharmacokinetic properties of fenofibrate.
Molecular pharmaceutics.
2013 Jul; 10(7):2723-9. doi:
10.1021/mp400133j. [PMID: 23672178] - Ariel Brautbar, Maja Barbalic, Fengju Chen, John Belmont, Salim S Virani, Steve Scherer, Robert A Hegele, Christie M Ballantyne. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
Journal of lipid research.
2013 Jul; 54(7):1980-7. doi:
10.1194/jlr.m034132. [PMID: 23633496] - Qiang Geng, Jingyi Ren, Hong Chen, Chongyou Lee, Wenqing Liang. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Current medical research and opinion.
2013 Mar; 29(3):181-8. doi:
10.1185/03007995.2013.766592. [PMID: 23323878] - Eli M Roth, Robert S Rosenson, Peter H Jones, Michael H Davidson, Maureen T Kelly, Carolyn M Setze, Aditya Lele, Kamlesh Thakker. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Journal of clinical lipidology.
2012 Nov; 6(6):534-44. doi:
10.1016/j.jacl.2012.02.002. [PMID: 23312049] - Li Ma, Christie M Ballantyne, John W Belmont, Alon Keinan, Ariel Brautbar. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Journal of lipid research.
2012 Nov; 53(11):2425-8. doi:
10.1194/jlr.m028829. [PMID: 22896670] - Rina P M Wong, Timothy M E Davis. In vitro antimalarial activity and drug interactions of fenofibric acid.
Antimicrobial agents and chemotherapy.
2012 Jun; 56(6):2814-8. doi:
10.1128/aac.05076-11. [PMID: 22430967] - Theodosios D Filippatos. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Cardiovascular drugs and therapy.
2012 Jun; 26(3):245-55. doi:
10.1007/s10557-012-6394-0. [PMID: 22592524] - Guanxiong Wang, Jifen Guo, Fanhua Meng, Xiaomei Song, Bohua Zhong, Yimin Zhao. Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma.
Biomedical chromatography : BMC.
2012 Apr; 26(4):497-501. doi:
10.1002/bmc.1693. [PMID: 21882209] - Keith C Ferdinand, Michael H Davidson, Maureen T Kelly, Carolyn M Setze. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2012 Apr; 12(2):117-25. doi:
10.2165/11597940-000000000-00000. [PMID: 22263674] - Ariel Brautbar, Salim S Virani, John Belmont, Vijay Nambi, Peter H Jones, Christie M Ballantyne. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Journal of lipid research.
2012 Mar; 53(3):556-560. doi:
10.1194/jlr.m020404. [PMID: 22236405] - Christie M Ballantyne, Michael H Davidson, Carolyn M Setze, Maureen T Kelly. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
Journal of clinical lipidology.
2011 Sep; 5(5):401-7. doi:
10.1016/j.jacl.2011.06.010. [PMID: 21981842] - Babasaheb P Bandgar, Rajendra J Sarangdhar, Fruthous Khan, Jeyamurugan Mookkan, Pranesha Shetty, Gajendra Singh. Synthesis and biological evaluation of orally active hypolipidemic agents.
Journal of medicinal chemistry.
2011 Aug; 54(16):5915-26. doi:
10.1021/jm200704f. [PMID: 21770455] - Anne C Goldberg, Vera Bittner, Carl J Pepine, Maureen T Kelly, Kamlesh Thakker, Carolyn M Setze, Aditya Lele, Darryl J Sleep. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
The American journal of cardiology.
2011 Mar; 107(6):898-905. doi:
10.1016/j.amjcard.2010.11.009. [PMID: 21247520] - Robert S Rosenson, Dawn M Carlson, Maureen T Kelly, Carolyn M Setze, Boaz Hirshberg, James C Stolzenbach, Laura A Williams. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Cardiovascular drugs and therapy.
2011 Feb; 25(1):47-57. doi:
10.1007/s10557-010-6273-5. [PMID: 21174145] - Christie M Ballantyne, Peter H Jones, Maureen T Kelly, Carolyn M Setze, Aditya Lele, Kamlesh M Thakker, James C Stolzenbach. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Cardiovascular drugs and therapy.
2011 Feb; 25(1):59-67. doi:
10.1007/s10557-011-6280-1. [PMID: 21416219] - Krzysztof Łabuzek, Łukasz Bułdak, Anna Duława-Bułdak, Anna Bielecka, Robert Krysiak, Andrzej Madej, Bogusław Okopień. Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.
Pharmacological reports : PR.
2011; 63(5):1124-36. doi:
10.1016/s1734-1140(11)70631-4. [PMID: 22180354] - Eli M Roth, Robert S Rosenson, Dawn M Carlson, Sandra M Fukumoto, Carolyn M Setze, James W Blasetto, Nardev S Khurmi, James C Stolzenbach, Laura A Williams. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Cardiovascular drugs and therapy.
2010 Dec; 24(5-6):421-8. doi:
10.1007/s10557-010-6266-4. [PMID: 20953684] - Tânia Vieira Madureira, Juliana Cristina Barreiro, Maria João Rocha, Eduardo Rocha, Quezia Bezerra Cass, Maria Elizabeth Tiritan. Spatiotemporal distribution of pharmaceuticals in the Douro River estuary (Portugal).
The Science of the total environment.
2010 Oct; 408(22):5513-20. doi:
10.1016/j.scitotenv.2010.07.069. [PMID: 20732709] - Carl J Pepine, Terry A Jacobson, Dawn M Carlson, Maureen T Kelly, Carolyn M Setze, Alex Gold, James C Stolzenbach, Laura A Williams. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
Clinical cardiology.
2010 Oct; 33(10):609-619. doi:
10.1002/clc.20830. [PMID: 20960535] - Peter H Jones, Anne C Goldberg, Howard R Knapp, Maureen T Kelly, Carolyn M Setze, James C Stolzenbach, Darryl J Sleep. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
American heart journal.
2010 Oct; 160(4):759-66. doi:
10.1016/j.ahj.2010.06.045. [PMID: 20934572] - J Campbell, S M Mohiuddin. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Drugs of today (Barcelona, Spain : 1998).
2010 Oct; 46(10):757-64. doi:
10.1358/dot.2010.46.10.1519652. [PMID: 21076712] - Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf, Haralampos J Milionis. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Vascular health and risk management.
2010 Aug; 6(?):525-39. doi:
10.2147/vhrm.s5593. [PMID: 20730069] - Tong Zhu, Jean-Claude Ansquer, Maureen T Kelly, Darryl J Sleep, Rajendra S Pradhan. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Journal of clinical pharmacology.
2010 Aug; 50(8):914-21. doi:
10.1177/0091270009354995. [PMID: 20145261] - Jannes Woudenberg, Krzysztof P Rembacz, Fiona A J van den Heuvel, Titia E Woudenberg-Vrenken, Manon Buist-Homan, Mariska Geuken, Mark Hoekstra, Leo E Deelman, Carlos Enrich, Rob H Henning, Han Moshage, Klaas Nico Faber. Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes.
Hepatology (Baltimore, Md.).
2010 May; 51(5):1744-53. doi:
10.1002/hep.23460. [PMID: 20146263] - Szilard Voros, Parag H Joshi, Gustavo Vazquez, Gina Roth, Laura Murrieta, Sarah Rinehart, Zhen Qian, Joseph Miller. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.
Journal of cardiovascular computed tomography.
2010 May; 4(3):164-72. doi:
10.1016/j.jcct.2010.03.005. [PMID: 20413364] - Susan M Schima, Stephanie R Maciejewski, Daniel E Hilleman, Mark A Williams, Syed M Mohiuddin. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Expert opinion on pharmacotherapy.
2010 Apr; 11(5):731-8. doi:
10.1517/14656560903575639. [PMID: 20210682] - Peter H Jones, Kenneth Cusi, Michael H Davidson, Maureen T Kelly, Carolyn M Setze, Kamlesh Thakker, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2010; 10(2):73-84. doi:
10.2165/10061630-000000000-00000. [PMID: 20136164] - Mark S Kipnes, Eli M Roth, James M Rhyne, Carolyn M Setze, Aditya Lele, Maureen T Kelly, Darryl J Sleep, James C Stolzenbach. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Clinical drug investigation.
2010; 30(1):51-61. doi:
10.2165/11319800-000000000-00000. [PMID: 19995098] - Eli M Roth, James M McKenney, Maureen T Kelly, Carolyn M Setze, Dawn M Carlson, Alex Gold, James C Stolzenbach, Laura A Williams, Peter H Jones. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2010; 10(3):175-86. doi:
10.2165/11533430-000000000-00000. [PMID: 20524719] - Robert Krysiak, Krzysztof Labuzek, Bogusław Okopień. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects.
Pharmacological reports : PR.
2009 Nov; 61(6):1134-45. doi:
10.1016/s1734-1140(09)70176-8. [PMID: 20081249] - Jelena Tojcic, Marie-Odile Benoit-Biancamano, Michael H Court, Robert J Straka, Patrick Caron, Chantal Guillemette. In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals.
2009 Nov; 37(11):2236-43. doi:
10.1124/dmd.109.029058. [PMID: 19661212] - Dasandi Bhavesh, Sanjay Shah. Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study.
Biomedical chromatography : BMC.
2009 Sep; 23(9):922-8. doi:
10.1002/bmc.1203. [PMID: 19353730] - Terry A Jacobson. Myopathy with statin-fibrate combination therapy: clinical considerations.
Nature reviews. Endocrinology.
2009 Sep; 5(9):507-18. doi:
10.1038/nrendo.2009.151. [PMID: 19636324] - Peter H Jones, Michael H Davidson, Moti L Kashyap, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Atherosclerosis.
2009 May; 204(1):208-15. doi:
10.1016/j.atherosclerosis.2008.09.027. [PMID: 18996523] - Anne C Goldberg, Harold E Bays, Christie M Ballantyne, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
The American journal of cardiology.
2009 Feb; 103(4):515-22. doi:
10.1016/j.amjcard.2008.10.025. [PMID: 19195513] - Tong Zhu, Walid M Awni, Balakrishna Hosmane, Maureen T Kelly, Darryl J Sleep, James C Stolzenbach, Katty Wan, Titus O Chira, Rajendra S Pradhan. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Journal of clinical pharmacology.
2009 Jan; 49(1):63-71. doi:
10.1177/0091270008325671. [PMID: 18952910] - Syed M Mohiuddin, Carl J Pepine, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
American heart journal.
2009 Jan; 157(1):195-203. doi:
10.1016/j.ahj.2008.08.027. [PMID: 19081418] - Lily P H Yang, Gillian M Keating. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2009; 9(6):401-9. doi:
10.2165/11203920-000000000-00000. [PMID: 19929038] - Shigeru Nakano, Tatsuya Nagasawa, Tomoyuki Ijiro, Yoichi Inada, Toru Tamura, Kazuyasu Maruyama, Junji Kuroda, Yoshinobu Yamazaki, Hiroshi Kusama, Nobuo Shibata. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line.
Hepatology research : the official journal of the Japan Society of Hepatology.
2008 Oct; 38(10):1026-39. doi:
10.1111/j.1872-034x.2008.00363.x. [PMID: 18513333] - Petra Thulin, Ingalill Rafter, Kenneth Stockling, Celine Tomkiewicz, Ensio Norjavaara, Martine Aggerbeck, Heike Hellmold, Ewa Ehrenborg, Ulf Andersson, Ian Cotgreave, Björn Glinghammar. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.
Toxicology and applied pharmacology.
2008 Aug; 231(1):1-9. doi:
10.1016/j.taap.2008.03.007. [PMID: 18455211] - B Mertens, B Cahay, R Klinkenberg, B Streel. An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection.
Journal of chromatography. A.
2008 May; 1189(1-2):493-502. doi:
10.1016/j.chroma.2008.01.060. [PMID: 18342321] - Masaki Tsunoda, Naoki Kobayashi, Tomohiro Ide, Mari Utsumi, Michiaki Nagasawa, Koji Murakami. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
American journal of physiology. Endocrinology and metabolism.
2008 May; 294(5):E833-40. doi:
10.1152/ajpendo.00627.2007. [PMID: 18212024] - Sanae Kourimate, Cédric Le May, Cédric Langhi, Anne Laure Jarnoux, Khadija Ouguerram, Yassine Zaïr, Patrick Nguyen, Michel Krempf, Bertrand Cariou, Philippe Costet. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
The Journal of biological chemistry.
2008 Apr; 283(15):9666-73. doi:
10.1074/jbc.m705831200. [PMID: 18245819] - Peter H Jones, Harold E Bays, Michael H Davidson, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep, James C Stolzenbach. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Clinical drug investigation.
2008; 28(10):625-34. doi:
10.2165/00044011-200828100-00003. [PMID: 18783301] - Theunis C Goosen, Jonathan N Bauman, John A Davis, Chongwoo Yu, Susan I Hurst, J Andrew Williams, Cho-Ming Loi. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Aug; 35(8):1315-24. doi:
10.1124/dmd.107.015230. [PMID: 17470524] - Takafumi Nakamachi, Takashi Nomiyama, Florence Gizard, Elizabeth B Heywood, Karrie L Jones, Yue Zhao, Lucia Fuentes, Kohzo Takebayashi, Yoshimasa Aso, Bart Staels, Toshihiko Inukai, Dennis Bruemmer. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Diabetes.
2007 Jun; 56(6):1662-70. doi:
10.2337/db06-1177. [PMID: 17360982] - Robert J Straka, R Todd Burkhardt, James E Fisher. Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum.
Therapeutic drug monitoring.
2007 Apr; 29(2):197-202. doi:
10.1097/ftd.0b013e318030860a. [PMID: 17417074] - Chiyoko Kunishima, Ikuo Inoue, Toshihiro Oikawa, Hiromu Nakajima, Tsugikazu Komoda, Shigehiro Katayama. Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.
PPAR research.
2007; 2007(?):36092. doi:
10.1155/2007/36092. [PMID: 18274627] - Alexis Zamble, Marie Carpentier, Abdelmejid Kandoussi, Sevser Sahpaz, Olivier Petrault, Tawarak Ouk, Nathalie Hennuyer, Jean-Charles Fruchart, Bart Staels, Régis Bordet, Patrick Duriez, François Bailleul, Françoise Martin-Nizard. Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms.
Journal of cardiovascular pharmacology.
2006 Apr; 47(4):599-608. doi:
10.1097/01.fjc.0000211734.53798.1d. [PMID: 16680075] - Linda E Gustavson, Sarah M Schweitzer, David A Burt, Ramanuj Achari, Matthew J Rieser, Timi Edeki, Titus Chira, H Daniel Yannicelli, Maureen T Kelly. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Clinical therapeutics.
2006 Mar; 28(3):373-87. doi:
10.1016/j.clinthera.2006.03.009. [PMID: 16750452] - Keisuke Tachibana, Yumi Kobayashi, Toshiya Tanaka, Masayuki Tagami, Akira Sugiyama, Tatsuya Katayama, Chihiro Ueda, Daisuke Yamasaki, Kenji Ishimoto, Mikako Sumitomo, Yasutoshi Uchiyama, Takahide Kohro, Juro Sakai, Takao Hamakubo, Tatsuhiko Kodama, Takefumi Doi. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms.
Nuclear receptor.
2005 Oct; 3(?):3. doi:
10.1186/1478-1336-3-3. [PMID: 16197558] - Ravi Kumar Trivedi, Raja Reddy Kallem, Ramesh Mullangi, Nuggehally R Srinivas. Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.
Journal of pharmaceutical and biomedical analysis.
2005 Sep; 39(3-4):661-9. doi:
10.1016/j.jpba.2005.05.005. [PMID: 15970417] - Markus Neumeier, Johanna Weigert, Andreas Schäffler, Thomas Weiss, Stefan Kirchner, Sabine Laberer, Jürgen Schölmerich, Christa Buechler. Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
Biochemical and biophysical research communications.
2005 Sep; 334(3):924-9. doi:
10.1016/j.bbrc.2005.06.187. [PMID: 16023994] - M Yamazaki, B Li, S W Louie, N T Pudvah, R Stocco, W Wong, M Abramovitz, A Demartis, R Laufer, J H Hochman, T Prueksaritanont, J H Lin. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
Xenobiotica; the fate of foreign compounds in biological systems.
2005 Jul; 35(7):737-53. doi:
10.1080/00498250500136676. [PMID: 16316932] - Reijiro Arakawa, Norimasa Tamehiro, Tomoko Nishimaki-Mogami, Kazumitsu Ueda, Shinji Yokoyama. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.
Arteriosclerosis, thrombosis, and vascular biology.
2005 Jun; 25(6):1193-7. doi:
10.1161/01.atv.0000163844.07815.c4. [PMID: 15790930] - Sébastien Dharancy, Mathilde Malapel, Gabriel Perlemuter, Tania Roskams, Yang Cheng, Laurent Dubuquoy, Philippe Podevin, Filoména Conti, Valérie Canva, David Philippe, Luc Gambiez, Philippe Mathurin, Jean-Claude Paris, Kristina Schoonjans, Yvon Calmus, Stanislas Pol, Johan Auwerx, Pierre Desreumaux. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.
Gastroenterology.
2005 Feb; 128(2):334-42. doi:
10.1053/j.gastro.2004.11.016. [PMID: 15685545] - Kenji Kuwabara, Kohji Murakami, Makoto Todo, Tomiyoshi Aoki, Tetsuo Asaki, Masatoshi Murai, Junichi Yano. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.
The Journal of pharmacology and experimental therapeutics.
2004 Jun; 309(3):970-7. doi:
10.1124/jpet.103.064659. [PMID: 14982965] - Zak K Shihabi. Fenofibrate and fenofibric acid analysis by capillary electrophoresis.
Electrophoresis.
2004 Jun; 25(10-11):1648-51. doi:
10.1002/elps.200305849. [PMID: 15188253] - Yves Rival, Nathalie Benéteau, Violaine Chapuis, Thierry Taillandier, Fabrice Lestienne, Elisabeth Dupont-Passelaigue, Jean-François Patoiseau, Francis C Colpaert, Didier Junquéro. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
DNA and cell biology.
2004 May; 23(5):283-92. doi:
10.1089/104454904323090912. [PMID: 15169608] - Manuela Ehrhardt, Heike Lindenmaier, Juergen Burhenne, Walter Emil Haefeli, Johanna Weiss. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.
Biochemical pharmacology.
2004 Jan; 67(2):285-92. doi:
10.1016/j.bcp.2003.09.008. [PMID: 14698041] - Kazuo Sonoki, Masanori Iwase, Kenzo Iino, Kojiro Ichikawa, Mototaka Yoshinari, Shigehiro Ohdo, Shun Higuchi, Mitsuo Iida. Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells.
European journal of pharmacology.
2003 Aug; 475(1-3):139-47. doi:
10.1016/s0014-2999(03)02109-5. [PMID: 12954370] - Paul D Martin, Aaron L Dane, Dennis W Schneck, Michael J Warwick. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Clinical therapeutics.
2003 Feb; 25(2):459-71. doi:
10.1016/s0149-2918(03)80089-9. [PMID: 12749507] - G Martin, H Duez, C Blanquart, V Berezowski, P Poulain, J C Fruchart, J Najib-Fruchart, C Glineur, B Staels. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
The Journal of clinical investigation.
2001 Jun; 107(11):1423-32. doi:
10.1172/jci10852. [PMID: 11390424] - ". Choice of lipid-regulating drugs.
The Medical letter on drugs and therapeutics.
2001 May; 43(1105):43-8. doi:
". [PMID: 11378632] - A Minnich, N Tian, L Byan, G Bilder. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.
American journal of physiology. Endocrinology and metabolism.
2001 Feb; 280(2):E270-9. doi:
10.1152/ajpendo.2001.280.2.e270. [PMID: 11158930] - A S Wierzbicki, D P Mikhailidis, R Wray. Drug treatment of combined hyperlipidemia.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2001; 1(5):327-36. doi:
10.2165/00129784-200101050-00003. [PMID: 14728015] - B Streel, P Hubert, A Ceccato. Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications.
2000 Jun; 742(2):391-400. doi:
10.1016/s0378-4347(00)00195-x. [PMID: 10901144] - W J Pan, L E Gustavson, R Achari, M J Rieser, X Ye, C Gutterman, B A Wallin. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers.
Journal of clinical pharmacology.
2000 Mar; 40(3):316-23. doi:
10.1177/00912700022008874. [PMID: 10709162] - D R Guay. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
The Annals of pharmacotherapy.
1999 Oct; 33(10):1083-103. doi:
10.1345/aph.18432. [PMID: 10534222] - A Sabile, G Perlemuter, F Bono, K Kohara, F Demaugre, M Kohara, Y Matsuura, T Miyamura, C Bréchot, G Barba. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates.
Hepatology (Baltimore, Md.).
1999 Oct; 30(4):1064-76. doi:
10.1002/hep.510300429. [PMID: 10498661] - L Nilsson, T Takemura, P Eriksson, A Hamsten. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Arteriosclerosis, thrombosis, and vascular biology.
1999 Jun; 19(6):1577-81. doi:
10.1161/01.atv.19.6.1577. [PMID: 10364093] - M Kockx, P P Gervois, P Poulain, B Derudas, J M Peters, F J Gonzalez, H M Princen, T Kooistra, B Staels. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Blood.
1999 May; 93(9):2991-8. doi:
NULL. [PMID: 10216095]
